View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 9, 2021updated 11 Jul 2022 2:15pm

ICR says cancer trial enrolment drops during Covid-19 pandemic

Administrative burden, insufficient data are some of the issues identified by ICR for the decrease in recruitment.

The Institute of Cancer Research (ICR), London, in the UK has reported that the number of individuals with cancer entering clinical trials has dropped during the Covid-19 pandemic.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Estimates show that the 60% reduction in recruitment to cancer trials was noted during the first year of the pandemic.

In 2020-2021, the number of individuals with cancer enrolled into trials in England dropped to 27,734 from an average of 67,057 over the previous three years, the National Institute for Health Research (NIHR) figures showed.

These figures come amid warnings that the pandemic has intensified enduring problems with funding for trials, regulation and access.

A study conducted from April to July 2020 during the initial stages of the pandemic found that greater administrative burden in launching trials, specifically for novel trial designs such as biomarker-driven studies for precision therapeutic, led to reduced recruitment.

Other issues included the UK National Health Service not having mechanisms to perform quick genetic testing for patients to recruit them for precision therapy trials.

Furthermore, funding for doctors to conduct clinical research differs and insufficient data on trials are available to patients and doctors.

The ICR further added that there is a disparity to access trials throughout the country, with some patients in rural regions reporting travelling more than 100 miles to receive a trial treatment.

ICR chief executive professor Kristian Helin said: “Clinical trials have huge benefits for patients, both by providing access to the latest drugs and technologies and by demonstrating the effectiveness of the next generation of treatments for use on the NHS.

“We would like to see a clinical trial being made available for every cancer patient who would like to participate in one.

“That requires both investment in Covid-19 clinical research recovery, to get us back to where we were before the pandemic, and broader measures to widen access to trials by reshaping funding, regulation, information and treatment pathways.”

This October, the ICR reported that a cocktail of immunotherapies could be effective as first-line therapy to treat relapsed or metastatic head and neck cancer patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena